Mukaiyama T
Department of Palliative Medicine and Medical Oncology, Tokyo Metropolitan Toshima General Hospital, 33-1 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan.
Gan To Kagaku Ryoho. 2001 Jul;28(7):883-91.
About half of patients with cancer will suffer from wasting syndrome, called cancer cachexia, which shows abnormality of homeostasis, nutrition, endocrine function, metabolism, immunity et al. This syndrome is characterized with anorexia and weight loss caused by degradation of skeletal muscle and adipose tissue. Progressive weight loss is responsible not only for a poor quality of life and poor response to anti-cancer drug, but also shorter survival time comparing patient without weight loss. Various factors have been found as mediators of this syndrome base on the development of immunology, biochemistry and molecular and cellular biology. These include several cytokines, proteolysis-inducing factor (PIF), lipid-mobilizing factor (LMF), apoptosis-inducing factor and another factors. Recentry, molecular biological analysis makes clear more detail mechanisms of cancer cachexia syndrome, for example, ubiqutin/proteasome pathway, activation of nuclear transcriptional factors and others. These progresses will contribute not only to establish new treatment but also to carry out "order-made palliative oncology" using DNA-chip and/or Protein-chip in near future.
约半数癌症患者会罹患一种称为癌症恶病质的消耗综合征，该综合征表现为体内稳态、营养、内分泌功能、代谢、免疫等方面的异常。此综合征的特征是由骨骼肌和脂肪组织退化导致的厌食和体重减轻。进行性体重减轻不仅会导致生活质量下降以及对抗癌药物反应不佳，而且与未体重减轻的患者相比，还会缩短生存时间。基于免疫学、生物化学以及分子和细胞生物学的发展，已发现多种因素可作为该综合征的介质。这些因素包括几种细胞因子、蛋白水解诱导因子（PIF）、脂质动员因子（LMF）、凋亡诱导因子以及其他因素。近来，分子生物学分析更清楚地揭示了癌症恶病质综合征的详细机制，例如泛素/蛋白酶体途径、核转录因子的激活等。这些进展不仅将有助于建立新的治疗方法，还将在不久的将来推动使用DNA芯片和/或蛋白质芯片开展“定制化姑息肿瘤学”。
